Merck

Alzheimer’s plasma biomarker study yields potential for diagnostic blood tests

Friday, March 30, 2012 09:10 AM

Proteome Sciences, in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, has completed its 1,000-sample Alzheimer’s disease (AD) biomarker validation study.

More... »

Merck’s efficiency program to make cuts across all businesses and regions

Monday, February 27, 2012 03:15 PM

Merck's executive board has presented initial plans for an efficiency program spanning all businesses as part of the company's comprehensive transformation program announced last year.

More... »

Threshold, Merck to collaborate

Monday, February 6, 2012 01:51 PM

Threshold Pharmaceuticals has signed a global agreement with Germany-based Merck to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

Study finds Gardasil does not trigger lupus, type I diabetes

Wednesday, January 25, 2012 04:19 PM

Gardasil, the HPV vaccine recommended for male and female adolescents and young adults, does not trigger autoimmune conditions such as lupus, type 1 diabetes or multiple sclerosis after vaccination in young women, according to a new study in the Journal of Internal Medicine, conducted by Kaiser Permanente.

More... »

ProTrials creates U.K. subsidiary

Tuesday, January 24, 2012 10:40 AM

Sunnyvale, Calif.-based CRO ProTrials Research has created a wholly owned subsidiary to help meet its sponsors’ increasing needs for multi-national, multi-site clinical trials.  Based in the United Kingdom, ProTrials Global will help manage ongoing clinical trials in Italy, Spain and the U.K., and will be responsible for additional growth in the European arena.

More... »

Merck inks license agreement with Exelisis for P13K-Delta program

Wednesday, December 21, 2011 11:57 AM

Exelixis has granted to Merck an exclusive worldwide license to its PI3K-delta research and development program, including XL499, the company’s most advanced preclinical PI3K-delta inhibitor and other related compounds. Under the agreement, Merck will have a worldwide exclusive license and have sole responsibility to research, develop, and commercialize compounds originating from the program.

More... »

Mochida inks license agreement with Merck

Tuesday, December 13, 2011 12:00 PM

Mochida Pharmaceutical has entered into a license agreement with Merck, through a subsidiary, relating to a portfolio of drug candidates invented by Mochida for the potential treatment for type-2 diabetes. Under the terms of the agreement, Merck has been granted a worldwide exclusive license to develop, manufacture, use and sell the potential drug candidates. Mochida will receive from Merck an upfront payment and potential development milestone payments, as well as royalties on the sales of any products derived from the collaboration. Mochida has retained an option to co-develop and co-market any products in Japan.

More... »

NanoBio, Merk collaborate in RSV research

Friday, December 9, 2011 09:30 AM

NanoBio has formed a preclinical collaboration with a subsidiary of Merck, focused on the development of a vaccine for Respiratory Syncytial Virus (RSV). The studies will evaluate the combination of Merck’s proprietary RSV antigen with NanoBio’s NanoStat adjuvant technology for use as an intranasal vaccine. As part of the agreement, Merck has the option to negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.

More... »

Ezose Sciences partners with Merck to advance biomarker discovery in diabetes

Friday, December 9, 2011 08:35 AM

Ezose Sciences has entered an agreement with Merck, through a subsidiary, to collaborate on biomarker discovery research in the field of diabetes. The collaboration seeks to identify glycans, the complex carbohydrate component of glycoproteins, which can play a role in health and disease.

More... »